AbolerIS Pharma
Biotechnology company that will develop novel and unique therapeutic approaches to induce immune tolerance and preserves useful immune responses in inflammatory, autoimmune and degenerative diseases.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor | €0.0 | round | |
| investor investor investor | €0.0 | round | |
* | €27.3m | Series A | |
| Total Funding | 000k | ||
Related Content
AbolerIS Pharma is a biotech company based in Nantes, France, that is currently in the pre-clinical stage. The company's primary focus is on the development of innovative immunomodulators. These are substances that help regulate the immune system, which can be crucial in treating conditions like transplant rejection, graft-versus-host-disease, and various autoimmune disorders.
The company's target market is primarily in the healthcare sector, specifically those dealing with transplants and autoimmune diseases. This includes hospitals, clinics, and potentially pharmaceutical companies that could distribute their products once they are fully developed and approved.
AbolerIS Pharma's business model is centered around research and development. They invest in creating new, innovative immunomodulators, which they aim to patent and sell or license to healthcare providers or pharmaceutical companies. The company generates revenue through these sales or licensing deals.
Despite being a relatively young company, AbolerIS Pharma has shown significant growth and resilience over the past four years. They have successfully navigated challenges and seized new opportunities, demonstrating their potential for future success.
The company also values knowledge sharing and collaboration, as evidenced by their participation in international conferences and events. This not only helps them stay updated with the latest advancements in their field but also provides opportunities for networking and potential partnerships.
Keywords: Biotech, Immunomodulators, Pre-clinical stage, Transplant rejection, Graft-versus-host-disease, Autoimmune disorders, Research and Development, Healthcare sector, Pharmaceutical companies, Licensing.